Camad, Naima T.
HRN: 27-25-64 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/06/2025
CO-AMOXICLAV 625MG (TAB)
06/06/2025
06/12/2025
ORAL
625mg
Every 8 Hours
Premature Rupture Of Membranes
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes